Summit Creek Advisors LLC Buys New Stake in Tabula Rasa HealthCare Inc (TRHC)

Share on StockTwits

Summit Creek Advisors LLC acquired a new position in shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 51,130 shares of the company’s stock, valued at approximately $2,885,000. Summit Creek Advisors LLC owned approximately 0.24% of Tabula Rasa HealthCare at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. First Mercantile Trust Co. acquired a new position in Tabula Rasa HealthCare during the 4th quarter worth approximately $39,000. TCI Wealth Advisors Inc. increased its position in Tabula Rasa HealthCare by 1,600.0% during the 4th quarter. TCI Wealth Advisors Inc. now owns 850 shares of the company’s stock worth $54,000 after purchasing an additional 800 shares in the last quarter. Quantamental Technologies LLC acquired a new position in Tabula Rasa HealthCare during the 4th quarter worth approximately $64,000. Oppenheimer Asset Management Inc. acquired a new position in Tabula Rasa HealthCare during the 4th quarter worth approximately $135,000. Finally, LS Investment Advisors LLC increased its position in Tabula Rasa HealthCare by 19.9% during the 4th quarter. LS Investment Advisors LLC now owns 2,813 shares of the company’s stock worth $179,000 after purchasing an additional 466 shares in the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

TRHC traded down $0.49 during trading on Monday, reaching $55.50. 4,726 shares of the company’s stock were exchanged, compared to its average volume of 325,544. Tabula Rasa HealthCare Inc has a one year low of $39.06 and a one year high of $91.16. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.84 and a quick ratio of 0.79. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 164.18 and a beta of 1.65.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Thursday, February 28th. The company reported $0.05 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.07). Tabula Rasa HealthCare had a positive return on equity of 7.76% and a negative net margin of 23.14%. The business had revenue of $57.31 million for the quarter, compared to the consensus estimate of $55.70 million.

In other news, CFO Brian W. Adams sold 684 shares of the company’s stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $60.00, for a total value of $41,040.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.50, for a total transaction of $436,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 50,000 shares of company stock worth $2,872,940 over the last three months. Insiders own 14.00% of the company’s stock.

A number of equities analysts recently issued reports on TRHC shares. Oppenheimer lowered their price objective on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, March 6th. BidaskClub cut shares of Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 9th. Benchmark started coverage on shares of Tabula Rasa HealthCare in a research report on Tuesday, January 8th. They set a “buy” rating and a $85.00 price objective for the company. Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Wednesday, December 19th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $99.00 target price on shares of Tabula Rasa HealthCare in a report on Thursday, February 28th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $83.48.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4294780/summit-creek-advisors-llc-buys-new-stake-in-tabula-rasa-healthcare-inc-trhc.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: What is a Swap?

Want to see what other hedge funds are holding TRHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare Inc (NASDAQ:TRHC).

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$3.37 Million in Sales Expected for Viveve Medical Inc  This Quarter
$3.37 Million in Sales Expected for Viveve Medical Inc This Quarter
Ren  Price Hits $0.0250 on Major Exchanges
Ren Price Hits $0.0250 on Major Exchanges
Viuly  1-Day Trading Volume Tops $218.00
Viuly 1-Day Trading Volume Tops $218.00
Bolenum  Price Hits $0.0000 on Major Exchanges
Bolenum Price Hits $0.0000 on Major Exchanges
Finjan Holdings Inc  Given Consensus Recommendation of “Strong Buy” by Analysts
Finjan Holdings Inc Given Consensus Recommendation of “Strong Buy” by Analysts
Align Technology  Issues Q2 2019 Earnings Guidance
Align Technology Issues Q2 2019 Earnings Guidance


© 2006-2019 Ticker Report